Working... Menu

Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00533936
Recruitment Status : Unknown
Verified March 2008 by National Cancer Institute (NCI).
Recruitment status was:  Recruiting
First Posted : September 24, 2007
Last Update Posted : August 26, 2013
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving combination chemotherapy together with trastuzumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving trastuzumab after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the tumor may not need more treatment until it progresses. In this case, observation may be sufficient. It is not yet known whether trastuzumab is more effective than observation when given after combination chemotherapy and trastuzumab in treating patients with breast cancer.

PURPOSE: This randomized phase II trial is studying trastuzumab to see how well it works compared with observation when given after combination chemotherapy and trastuzumab in treating patients undergoing surgery for stage II or stage III breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Biological: trastuzumab Drug: cyclophosphamide Drug: doxorubicin hydrochloride Drug: fluorouracil Drug: paclitaxel Procedure: adjuvant therapy Procedure: conventional surgery Procedure: neoadjuvant therapy Phase 2

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Adjuvant Trastuzumab vs Observation in Locally Advanced Breast Cancer Treated With Neoadjuvant Trastuzumab
Study Start Date : September 2006
Estimated Primary Completion Date : December 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Trastuzumab

Primary Outcome Measures :
  1. Percentage of pathological responses
  2. Disease-free survival

Secondary Outcome Measures :
  1. Overall survival at 3 years
  2. Cardiac toxicity
  3. Percentage of patients that become negative on the fluorescence in situ hybridization (FISH) test at the end of neoadjuvant therapy

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed invasive breast cancer by needle biopsy

    • Diagnosed within the past 4 weeks
    • Clinical stage IIB, IIIA, IIIB, or IIIC disease
  • Palpable adenopathies present
  • HER2/neu-positive disease, as evidenced by either of the following:

    • HER2/neu overexpression (3+) by immunohistochemistry (IHC)
    • HER2/neu amplification by fluorescence in situ hybridization (FISH)
  • No metastatic disease by chest radiography, hepatic ultrasound, and bone scan (metastatic bone series if no nuclear medicine is available)
  • Hormone receptor status:

    • Estrogen receptor and/or progesterone receptor status known


  • Premenopausal or postmenopausal
  • WHO performance status 0-2
  • Not pregnant or nursing
  • Normal hepatic, renal, and hematological function
  • LVEF ≥ 55% by nuclear medicine study or echocardiogram
  • No prior history of cancer, except carcinoma in situ of the cervix
  • No allergic reaction or hypersensitivity to paclitaxel and/or trastuzumab (Herceptin®)


  • No prior cancer therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00533936

Layout table for location information
Instituto Nacional de Cancerologia Recruiting
Mexico City, Distrito Federal, Mexico, 14000
Contact: Claudia Arce-Salinas, MD    52-55-5628-0400      
Hospital General de Mexico Recruiting
Mexico City, Distrito Federal, Mexico, C.P. 06726
Contact: Contact Person    52-55-5999-6133      
Sponsors and Collaborators
Instituto Nacional de Cancerologia, Columbia
Layout table for investigator information
Principal Investigator: Claudia Arce-Salinas, MD Instituto Nacional de Cancerologia, Columbia

Layout table for additonal information Identifier: NCT00533936     History of Changes
Other Study ID Numbers: CDR0000557417
First Posted: September 24, 2007    Key Record Dates
Last Update Posted: August 26, 2013
Last Verified: March 2008

Keywords provided by National Cancer Institute (NCI):
stage II breast cancer
stage IIIA breast cancer
stage IIIB breast cancer
stage IIIC breast cancer

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Liposomal doxorubicin
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Antineoplastic Agents, Immunological
Antimetabolites, Antineoplastic